Protagonist Therapeutics rose 47.3% from $84.20 to $124.02, ahead of the S&P 500's +9.7%. Its worst day was Oct 16 (−5.7%), and its low came Jan 29 at $79.73.
Story events cover the past 12 months · Times ET
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Protagonist Therapeutics closed at its lowest level of the year, 5.3% below where the year started.
−2.5% · S&P 500 −0.2%
EPS of $-0.69 missed the $-0.54 estimate on $7.4M revenue (est. $14.3M).
−0.3% · S&P 500 +0.8%
Protagonist Therapeutics shares rose 7.3%, while the S&P 500 rose 1.2%.
+7.3% · S&P 500 +1.2%
EPS of $0.05 beat the $-0.65 estimate on $56.4M revenue (est. $14.0M).
+4.8% · S&P 500 +1.4%
Protagonist Therapeutics shares rose 8.0%, while the S&P 500 fell 0.3%.
+8.0%, the year's best day · S&P 500 −0.3%
Protagonist Therapeutics shares rose 7.1%, while the S&P 500 fell 0.5%.
+7.1% · S&P 500 −0.5%
Protagonist Therapeutics shares rose 6.7%, while the S&P 500 fell 1.0%.
+6.7% · S&P 500 −1.0%
EPS of $2.29 beat the $1.84 estimate on $213.5M revenue (est. $213.1M).
+6.5% · S&P 500 −0.2%
Protagonist Therapeutics closed at its highest level of the year, 88.4% above where the year started.
+2.3% · S&P 500 −0.5%
EPS of $3.07 beat the $2.64 estimate on $274.4M revenue (est. $246.5M).
−2.4% · S&P 500 +0.3%
Where it ended: a close of $124.02 on Nov 19, 2026. Up next: Q4 2026 earnings on Feb 24, 2027 (EPS est. $-0.27, revenue est. $42.8M).
Nothing in the past 12 months.
All PTGX dividend history